News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Jan 22, 2021

Summary Toggle aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases

Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Research approach led to the identification of target receptors for two tRNA synthetases and further validates company’s biology platform. SAN DIEGO , Jan.
Jan 14, 2021

Summary Toggle aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan

SAN DIEGO , Jan. 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd.
Jan 7, 2021

Summary Toggle aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

SAN DIEGO , Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer,
Jan 4, 2021

Summary Toggle aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days. 83% of patients receiving 3.0 mg/kg dose of ATYR1923 achieved recovery in less than a week.
Dec 21, 2020

Summary Toggle aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

SAN DIEGO , Dec. 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has completed the target enrollment in its Phase 1b/2a clinical
Nov 12, 2020

Summary Toggle aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update

Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug candidate in oncology, ATYR2810, from its NRP2 antibody program.
Nov 11, 2020

Summary Toggle aTyr Pharma Announces Publication in the Journal mAbs

Peer-reviewed paper supports aTyr’s antibody program . Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO , Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based
Nov 10, 2020

Summary Toggle aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

Discovery advances the understanding of extracellular tRNA synthetase pathways . Findings may contribute to the development of new therapeutic s to treat cancer and fibrosis . SAN DIEGO , Nov. 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the
Nov 5, 2020

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST

SAN DIEGO , Nov. 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2020 financial results and provide a
Oct 29, 2020

Summary Toggle aTyr Pharma Announces Research Collaboration with Medical University of South Carolina

Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology . SAN DIEGO , Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative